Zobrazeno 1 - 7
of 7
pro vyhledávání: '"David Vesole"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Mary Brush, Bruce A. Cohen, Richard M. Pope, M. Fishman, Charles L. Goolsby, Philip Rowlings, James W. Schroeder, David Vesole, Karyn H. Karlin, M. Villa, Richard K. Burt, William H. Burns, Carolyn A. Keever-Taylor, Floyd A. Davis, Cass Terry, Steve Rosen, Salim Mujias, Dusan Stefoski, Ann E. Traynor, Lorri Lobeck
Publikováno v:
Blood. 92:3505-3514
Multiple sclerosis, systemic lupus erythematosus, and rheumatoid arthritis are immune-mediated diseases that are responsive to suppression or modulation of the immune system. For patients with severe disease, immunosuppression may be intensified to t
Autor:
Athanasios B-T, Fassas, Bart, Barlogie, Susan, Ward, Sundar, Jagannath, David, Vesole, Sandy, Mattox, David, Siegel, Firas, Muwalla, Maurizio, Zangari, Elias, Anaissie, Frits Van, Rhee, Raymond, Thertulien, Choon-Kee, Lee, Raman, Desikan, Varant, Arzumanian, Jason, McCoy, Guido, Tricot
Publikováno v:
British journal of haematology. 123(3)
Despite the superiority of high-dose (compared with standard) treatment in multiple myeloma, relapses still occur. We evaluated relapse patterns, salvage treatments employed and outcome in patients given tandem transplants on our total therapy I prot
Autor:
Raman Desikan, Bart Barlogie, Jeffrey Sawyer, Dan Ayers, Guido Tricot, Ashraf Badros, Maurizio Zangari, Nikhil C. Munshi, Elias Anaissie, Dan Spoon, David Siegel, Sundar Jagannath, David Vesole, Joshua Epstein, John Shaughnessy, Athanasios Fassas, Seah Lim, Paula Roberson, John Crowley
Publikováno v:
Blood. 95(12)
High-dose therapy (HDT) has increased complete remission (CR) rates and survival in multiple myeloma (MM). We now report on continuous CR (CCR) and associated prognostic factors in 1000 consecutive patients receiving melphalan-based tandem HDT. Five-
Autor:
S. Vincent Rajkumar, Susanna Jacobus, Natalie Callander, Rafael Fonseca, David Vesole, Michael Williams, Rafat Abonour, David Siegel, Philip Greipp
Publikováno v:
Blood. 110:74-74
Aim: A phase III trial of lenalidomide plus high (standard) dose dex (RD) versus lenalidomide plus low dose dex (Rd) in newly diagnosed myeloma (MM). Methods: Pts with untreated, symptomatic MM were eligible. Pts in the RD arm (Arm A) received lenali
Autor:
Pieter Sonneveld, Sagar Lonial, Sergio Giralt, Henk M. Lokhorst, Christina Gasparreto, Raymond L. Comenzo, Jenny Bird, Bart Barlogie, Amitabha Mazumder, Shaji Kumar, Brian G.M. Durie, Hans Erik Johnsen, Edward A. Stadtmauer, Paul G. Richardson, Muzaffer Qazilbash, Saad Z. Usmani, Gösta Gahrton, Heinz Ludwig, William I. Bensinger, P. Moreau, Paremesweran Hari, Charles F. LeMaistre, David H. Vesole, H. Goldschmidt, Amrita Krishnan, Gordon Cook, Vincent Rajkumar, Antonio Palumbo, Hareth Nahi, Jin Lu, Maria V. Mateos, Michele Cavo, Joan Bladé, Javier de la Rubia, Jesús F. San Miguel, Sundar Jagannath, Christopher Bredeson, Meletios A. Dimopoulos, Ramón García-Sanz, Robert A. Kyle, Joseph R. Mikhael, P.L. McCarthy, Rafat Abonour, Yvonne A. Efebera, Eloisa Riva, M. Mohty, Robert Z. Orlowski, Douglas E. Joshua, Benedetto Bruno, Anil Nooka, Laurent Garderet, Marcelo C. Pasquini, Peter Gimsing, Ingemar Turreson, Sarah A. Holstein, Anthony Reiman, Guenther Koehne, Michel Attal, James Gajewski, Hermann Einsele, Jens Hillengass, Nicolaus Kroeger, Xavier Leleu, Kenneth C. Anderson, Orhan Sezer
Publikováno v:
Biology of Blood and Marrow Transplantation, 21(12), 2039-2051. Elsevier Inc.
Giralt, S, Garderet, L, Durie, B, Cook, G, Gahrton, G, Bruno, B, Hari, P, Lokhorst, H, McCarthy, P, Krishnan, A, Sonneveld, P, Goldschmidt, H, Jagannath, S, Barlogie, B, Mateos, M, Gimsing, P, Sezer, O, Mikhael, J, Jin, L, Dimopoulos, M, Mazumder, A, Palumbo, A, Abonour, R, Anderson, K, Attal, M, Blade, J, Bird, J, Cavo, M, Comenzo, R, de la Rubia, J, Einsele, H, Garcia Sanz, R, Hillengass, J, Holstein, S, Johnsen, H E, Joshua, D, Koehne, G, Kumar, S, Kyle, R, Leleu, X, Lonial, S, Ludwig, H, Nahi, H, Nooka, A, Orlowski, R, Rajkumar, V, Reiman, A, Richardson, P, Rivas, E, San Miguel, J, Turreson, I, Usmani, S, Vesole, D, Bensinger, W, Qazilbash, M, Efebera, Y, Mohty, M, Gasparreto, C, Gajewski, J, LeMaistre, C, Bredeson, C, Moreau, P, Pasquini, M, Kroeger, N & Stadtmauer, E 2015, ' American Society of Blood and Marrow Transplant, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma ', Biology of Blood and Marrow Transplantation, vol. 21, no. 12, pp. 2039-2051 . https://doi.org/10.1016/j.bbmt.2015.09.016
Giralt, S, Garderet, L, Durie, B, Cook, G, Gahrton, G, Bruno, B, Hari, P, Lokhorst, H, McCarthy, P, Krishnan, A, Sonneveld, P, Goldschmidt, H, Jagannath, S, Barlogie, B, Mateos, M, Gimsing, P, Sezer, O, Mikhael, J, Jin, L, Dimopoulos, M, Mazumder, A, Palumbo, A, Abonour, R, Anderson, K, Attal, M, Blade, J, Bird, J, Cavo, M, Comenzo, R, de la Rubia, J, Einsele, H, Garcia Sanz, R, Hillengass, J, Holstein, S, Johnsen, H E, Joshua, D, Koehne, G, Kumar, S, Kyle, R, Leleu, X, Lonial, S, Ludwig, H, Nahi, H, Nooka, A, Orlowski, R, Rajkumar, V, Reiman, A, Richardson, P, Rivas, E, San Miguel, J, Turreson, I, Usmani, S, Vesole, D, Bensinger, W, Qazilbash, M, Efebera, Y, Mohty, M, Gasparreto, C, Gajewski, J, LeMaistre, C, Bredeson, C, Moreau, P, Pasquini, M, Kroeger, N & Stadtmauer, E 2015, ' American Society of Blood and Marrow Transplant, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma ', Biology of Blood and Marrow Transplantation, vol. 21, no. 12, pp. 2039-2051 . https://doi.org/10.1016/j.bbmt.2015.09.016
In contrast to the upfront setting in which the role of high-dose therapy with autologous hematopoietic cell transplantation (HCT) as consolidation of a first remission in patients with multiple myeloma (MM) is well established, the role of high-dose